Recent clinical trials in patients with heart failure with preserved ejection fraction (HFpEF) have provided important insights into participant selection strategies. Historically, HFpEF trials have included patients with relatively preserved left ventricular ejection fraction ranging from 40% to 55% and a clinical history of heart failure. Contemporary HFpEF trials have also incorporated inclusion criteria such as hospitalization for HFpEF, altered functional capacity, cardiac structural and functional abnormalities, and abnormalities in neurohormonal status (e.g., elevated natriuretic peptide levels). Careful analyses of the effect of these patient selection criteria on outcomes in prior trials provide valuable lessons for future trial design. We review recent and ongoing HFpEF clinical trials from a patient selection perspective and appraise trial patient selection methodologies in relation to outcomes. This review reflects discussions between clinicians, scientists, trialists, regulators, and regulatory representatives at the 10th Global CardioVascular Clinical Tria-
H eart failure with preserved ejection fraction (HFpEF) currently represents almost onehalf of all heart failure (HF) patients and, with the growing elderly population, is projected to become the predominant form of HF in the future (1, 2) . HFpEF represents a large unmet need in cardiovascular medicine. Over 5 million Americans and 23 million people worldwide have HF, of which patients with HFpEF constitute more than 50%, and this percentage will continue to rise with our aging population (1, (3) (4) (5) . In general, outcomes in HFpEF are similarly poor as those in patients with heart failure with reduced ejection fraction (HFrEF) with respect to hospitalization and mortality risk. Despite the therapeutic advances for patients with HFrEF through landmark clinical trials on neurohormonal modulation and device therapy, clinical trials in patients with HFpEF have been challenging, and results have been neutral. Important lessons can be learned from these prior trials. In this paper, we summarize recent and ongoing HFpEF clinical trials and appraise trial methodologies from the perspective of patient selection to critically inform the design of future randomized clinical trials for clinicians, researchers, and patients.
GUIDELINE DEFINITIONS FOR HFpEF
Recommendations for the diagnosis of patients with HFpEF are similar in scope and depth across the most recent U.S. and European guidelines (6-9). 
DEFINITIONS IN CLINICAL TRIALS
The first large clinical trial that focused on patients with HFpEF, the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) Preserved trial, required an EF >40%, New York Heart Association (NYHA) functional class II to IV symptoms for >4 weeks, and any prior hospital admission for a cardiac reason (13). This definition was analogous to HFrEF trials at the time, where EF cutpoints <35% and <45% were used in addition to HF symptoms or known history of HF (14, 15) . As the results from clinical trials and secondary analyses in these HFpEF populations without use of guideline criteria revealed low event rates and limited benefits from traditional HF therapies, clinical trialists subsequently adjusted entry criteria (16). The EF criterion was increased, echocardiographic parameters were incorporated, and eventually, natriuretic peptide (NP) levels were included in a combined definition that also required HF symptoms ( Table 2) . Preserved EF $50%, symptoms and/ or hospitalization for HF, echocardiographic findings, and elevated NP levels exemplified the prevailing thought that HFpEF was primarily a disease of elderly women with stiff left ventricles from longstanding hypertension and concomitant diabetes mellitus. However, clinical trials, cohort studies, and registry analyses have demonstrated that the HFpEF population is heterogeneous, particularly with respect to comorbidities (11). Future clinical trials in HFpEF may benefit from further refinement of these key patient selection criteria to optimize the potential for success.
EJECTION FRACTION
EF was the first inclusion criterion used to differentiate patients with HFrEF from HFpEF. The first 3 large HFpEF trials studied renin-angiotensin aldosterone system inhibition with EF cutoffs of 40% to 45% (13,17,18) . More recent trials have split between using an EF cutoff $45% and $50%. insightful use of EF as an inclusion criterion with an eye toward the preferred HFpEF phenotype will lead to successful trials. For example, if a clinical trial is studying a pharmaceutical therapy aimed at HFpEF patients with hypertension and associated structural remodeling, then use of a higher EF (e.g., 50%) inclusion criterion will enrich the trial with the preferred phenotype. However, if a promising new therapy appears to work across a more heterogeneous HFpEF population, then use of a lower EF (e.g., 40%) inclusion criterion will potentially make the results of the trial generalizable. Ultimately, the use of EF as an inclusion criterion requires appropriate insight into the HFpEF phenotype that will benefit most from the therapy under investigation. 
Methodologies in HFpEF Clinical Trials
A P R I L 2 8 , 2 0 1 5 : 1 6 6 8 -8 2 In-hospital mortality Hospitalization for HFpEF is increasing relative to HFrEF, with in-hospital mortality for HFpEF declining over study period *NP levels are median levels unless otherwise specified, and if used as inclusion criteria they are listed with > or < symbols. †Data are in percentages or 100 patient-years and from placebo groups in clinical trials unless otherwise noted. ‡RELAX-AHF event rate is cardiovascular death or HF/renal failure hospitalization through day 60. 
ATRIAL FIBRILLATION
Atrial fibrillation is 1 of the most common comorbidities in patients with HFpEF and coexists in 21% to 34% of patients in large registries and 4% to 61% of patients in HFpEF clinical trials ( Table 2) . Cardiopulmonary exercise testing (CPET) provides additive information to hemodynamics that may help exclude HF with normal tests and confirm or suggest a HF diagnosis with abnormal results (66) . CPET measurements obtained during exercise, including the gas exchange parameters, peak VO 2 , and the slope of the relationship between ventilation and carbon dioxide production, are independently associated with mortality and are strong independent predictors of mortality (39) . A study evaluating serelaxin demonstrated significant reductions in peak PCWP without changes in cardiac index, and a CPET with echocardiography study in patients with HFpEF treated with ivabradine, which revealed improved metabolic equivalents, peak VO 2 , and reduced E/e 0 , provided the impetus to pursue larger clinical trials on these 2 promising therapies (67,68). Emerging and novel biomarkers, such as cystatin C, galectin-3, and growth differentiation factor-15, may help phenotype, risk-stratify, and identify patients with or at risk for HFpEF (77) (78) (79) . Evidence continues to mount from studies that evaluated isolated comorbidities, such as coronary disease (80) and diabetes mellitus (81) 
